Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Only 11 patients were enrolled in 2023….
View:
Post by Dumbeldorfwhite on Dec 22, 2023 7:26am

Only 11 patients were enrolled in 2023….

I went back to last years year end NR and there were 52 patients enrolled at that time. That is such a disappointing enrollment rate. What in the companies experience makes them think they will get 37 in a year?
Comment by Benedictus on Dec 22, 2023 10:20pm
The MD&A is the best resource to confirm this information. The Dec 2202 MD&A showed 57 enrolled and treated patients, so 6 patients have been enrolled and treated in 2023. The 37 patient goal by end of 2024 is an absolute mystery to me. Roger was less than forthright on that detail in his recent interview, so we are left to speculate. My guess is they expect a BTD approval to enable an ...more  
Comment by DJDawg on Dec 22, 2023 11:39pm
Enrollment has been slow. The fact that a Dana-Farber site popped up as a brand new web page in late Oct (not recruiting yet) makes one hope that there could be another set of sites to join the study. Dana-Farber is Harvard and when I looked they don't have any other nmibc studies recruiting. This means that there is less competition for patients to join one study over another. RDW - that ...more  
Comment by Kayz88 on Dec 23, 2023 12:36am
This? Dana-Farber
Comment by Kayz88 on Dec 23, 2023 12:37am
https://www.dana-farber.org/clinical-trials/21-224
Comment by DJDawg on Dec 23, 2023 10:48am
Yes. that one. When you look at the date that the page was made it dates from late Oct this year so someone put up the page new and they are hopefully finalizing things before switching to "enrolling now".
Comment by DeathXray33 on Dec 24, 2023 10:55am
My unsolicited opinion to certain posters here is ; forget about this company and buy a "Total stock market index fund" ...
Comment by Benedictus on Dec 23, 2023 11:22pm
Yes, let's hope so. Roger's exact words were "we're laying in guidelines and direction in order to treat those 37 patients in 2024". I have no idea what that means. Whether it's more CSS's or his expectation that BTD approval will dramatically hasten enrollment, hopefully we do see a material increase in enrollment.
Comment by Infinity on Dec 26, 2023 6:33am
Great points DJDawg.  It certainly appears TLT is adding one more clinical test facilty.  Highly respected Boston based Dana Farber.  Sad part is that TLT does not communicate their future plans or what is in the pipe line regarding Virus or Vaccine studies.  Hoping that RDW would take your suggestion on boosting the PR.  I think  that his past troubles with OSC may ...more  
Comment by Dumbeldorfwhite on Dec 23, 2023 3:13pm
6 patients in an entire year!?!?! Yet the fanboys here would never mention it. Serious question do the literally pay these sites to recruit people upfront?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250